AMRI Acquires Whitehouse Laboratories

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-01-06-2016, Volume 12, Issue 1

AMRI adds analytical capabilities to its outsourcing services offerings with the acquisition of Whitehouse Labs.

Albany Molecular Research Inc. (AMRI) announced on Dec. 15, 2015, that it has acquired all the outstanding equity interests of Whitehouse Laboratories for $54 million in cash, and an additional $2 million in shares of AMRI common stock contingent upon Whitehouse Labs achieving certain 2015 targets.

Whitehouse Labs, based in Lebanon, NJ, offers testing solutions for life sciences including materials and excipients, container qualification and container closure integrity testing, analytical chemistry, drug delivery systems and device qualification programs, packaging, distribution, and stability and storage programs.

In a statement announcing the acquisition, William S. Marth, AMRI's president and chief executive officer noted that Whitehouse Labs’ service offerings meet the needs of its customers and will augment the company’s discovery, development, and manufacturing services.